Dr. Reddy's Laboratories Ltd.

NSE: DRREDDY · Healthcare

₹1,373.00+0.51%06 Nov 2026

Ask the data

Instant answers about Dr. Reddy's Laboratories Ltd. — computed from its filings, no language model

Market cap₹1,14,646 cr

Current price₹1,373.00

High / Low₹1,376 / ₹1,136

P/E40.9

P/B2.95

Book value₹464.8

ROE7.2%

ROCE8.9%

Debt / equity0.15

Dividend yield0.58%

EPS (TTM)₹33.53

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 9 periods

	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	14,281	15,448	17,517	19,048	21,545	24,670	28,011	32,644	33,700
EBITDA	2,351	3,178	2,470	3,870	3,768	6,349	7,933	8,547	6,454
Operating margin	16.5%	20.6%	14.1%	20.3%	17.5%	25.7%	28.3%	26.2%	19.1%
Interest	79	89	98	97	96	143	171	283	374
Depreciation	1,077	1,135	1,163	1,229	1,165	1,250	1,470	1,704	2,059
Profit before tax	1,350	2,292	1,830	2,836	2,991	6,012	7,186	7,658	5,379
Tax	438	386	-140	932	879	1,541	1,623	1,954	1,235
Net profit	947	1,950	2,026	1,952	2,182	4,507	0	5,655	4,196
EPS ₹	57.08	117.53	122.22	117.67	131.57	271.47	335.22	67.89	50.41
Operating cash flow	—	—	—	—	2,811	5,887	4,543	4,643	5,674
Capex	—	—	—	—	1,905	1,886	2,744	3,440	3,840
Dividend paid	—	—	—	—	415	498	665	666	666
Total assets	22,544	22,466	23,225	26,617	29,747	32,285	38,864	49,427	58,123
Equity	12,572	14,024	15,599	17,642	19,212	23,286	28,255	33,550	37,892

Quarterly performance

last 35 quarters · ₹ crore

showing latest 8 of 35 periods

	MAR '18	JUN '18	SEP '18	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	3,554	3,736	3,818	3,865	4,030	3,858	4,813	4,397	4,449	4,426	4,911	4,942	4,768	4,945	5,787	5,338	5,475	5,233	6,332	6,790	6,315	6,758	6,903	7,237	7,114	7,696	8,038	8,381	8,528	8,572	8,828	8,753	7,546	8,100	8,698
Operating profit	564	769	759	805	819	742	1,064	-289	949	1,121	1,156	539	1,053	734	1,360	1,216	451	941	1,899	1,938	1,534	2,062	2,008	2,023	1,831	2,130	2,076	2,273	1,998	2,174	2,010	1,888	382	860	1,731
Operating margin	15.9%	20.6%	19.9%	20.8%	20.3%	19.2%	22.1%	-6.6%	21.3%	25.3%	23.5%	10.9%	22.1%	14.9%	23.5%	22.8%	8.2%	18.0%	30.0%	28.6%	24.3%	30.5%	29.1%	28.0%	25.7%	27.7%	25.8%	27.1%	23.4%	25.4%	22.8%	21.6%	5.1%	10.6%	19.9%
Other income	45	50	128	102	83	430	54	67	74	87	51	70	83	108	206	56	122	854	41	59	138	174	315	216	198	187	308	150	522	290	324	269	475	355	156
Interest	18	20	21	24	24	30	30	15	23	23	25	19	30	19	23	22	32	35	31	42	35	37	35	39	59	60	76	82	66	83	91	94	106	126	125
Depreciation	276	279	279	290	287	289	313	287	274	292	316	311	309	284	294	294	293	302	309	324	316	353	376	374	368	381	397	471	455	476	505	521	557	537	527
Profit before tax	314	521	588	592	590	853	774	-524	726	893	866	280	797	539	1,248	956	248	1,459	1,600	1,632	1,322	1,846	1,912	1,826	1,602	1,877	1,911	1,870	2,000	1,905	1,738	1,541	195	552	1,235
Tax	49	53	81	101	151	193	-321	32	-45	306	101	267	258	175	277	265	162	279	499	394	369	445	434	448	295	490	576	470	418	495	408	354	-22	118	314
Net profit	272	476	518	500	455	676	1,095	-538	781	587	772	28	557	380	996	0	97	1,189	1,114	0	960	1,405	0	0	0	1,392	1,256	1,414	1,593	1,418	1,347	1,210	221	444	925
EPS ₹	16.39	28.69	31.22	30.16	27.45	40.81	66.78	-32.48	47.12	35.87	46.54	1.68	33.61	22.95	60.03	42.75	5.84	71.64	67.13	74.91	57.79	84.55	89.09	82.94	78.66	83.61	15.08	16.97	19.12	17.04	16.18	14.53	2.65	5.33	11.10
Revenue YoY	—	—	—	—	13.4%	3.3%	26.1%	13.8%	10.4%	14.7%	2.0%	12.4%	7.2%	11.7%	17.8%	8.0%	14.8%	5.8%	9.4%	27.2%	15.3%	29.1%	9.0%	6.6%	12.6%	13.9%	16.5%	15.8%	19.9%	11.4%	9.8%	4.4%	-11.5%	-5.5%	-1.5%
Profit YoY	—	—	—	—	67.4%	42.1%	111.3%	-207.6%	71.5%	-13.2%	-29.5%	—	-28.7%	-35.2%	29.0%	-100.0%	-82.6%	212.6%	11.9%	—	889.8%	18.2%	-100.0%	—	-100.0%	-0.9%	—	—	—	1.8%	7.3%	-14.4%	-86.1%	-68.7%	-31.3%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Dr. Reddy's Laboratories Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	4,216	4,547	5,305	6,740	8,434	9,728	10,011	10,208	9,698
Operating profit	859	1,135	1,166	1,268	1,732	2,699	2,317	2,342	1,733
Operating margin	20.4%	25.0%	22.0%	18.8%	20.5%	27.7%	23.1%	22.9%	17.9%
Other income	82	184	140	356	311	214	297	307	604
Interest	18	11	5	64	61	78	64	64	57
Depreciation	194	222	248	301	—	380	490	649	735
Profit before tax	730	1,029	1,052	1,259	1,753	2,454	2,060	1,580	1,544
Tax	169	183	158	347	488	522	380	226	160
Net profit	561	846	893	912	1,265	1,933	1,679	1,354	1,384

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	850	764	989	1,089	939	1,042	1,145	1,198	1,126	1,051	1,172	1,271	1,297	1,390	1,347	1,697	1,647	1,608	1,788	1,805	2,109	2,158	2,362	1,822	2,708	2,584	2,615	2,690	2,481	2,151	2,689	2,526	2,896	2,429	2,357	2,142	2,628	2,568	2,360	2,090	2,254	2,523
Operating profit	113	47	203	271	149	161	278	321	295	245	273	316	274	343	233	612	257	207	193	278	430	539	485	153	1,000	915	631	810	597	154	756	661	912	426	342	236	547	641	309	148	314	536
Operating margin	13.3%	6.1%	20.5%	24.9%	15.9%	15.5%	24.3%	26.8%	26.2%	23.3%	23.3%	24.8%	21.1%	24.7%	17.3%	36.1%	15.6%	12.9%	10.8%	15.4%	20.4%	25.0%	20.5%	8.4%	36.9%	35.4%	24.1%	30.1%	24.1%	7.1%	28.1%	26.2%	31.5%	17.6%	14.5%	11.0%	20.8%	24.9%	13.1%	7.1%	13.9%	21.2%
Other income	74	57	50	29	16	15	22	23	13	36	112	21	52	37	29	56	13	24	263	30	164	28	89	33	33	63	84	92	55	63	87	91	59	35	122	392	64	89	60	49	40	48
Interest	2	2	0	2	4	6	6	4	0	3	5	0	0	1	4	15	16	17	16	17	15	12	18	14	24	21	19	15	16	14	19	21	14	14	15	13	12	16	16	16	19	13
Depreciation	39	41	48	45	48	48	52	52	55	55	61	57	61	64	66	69	73	75	84	73	76	79	—	89	94	98	99	105	121	127	137	141	159	167	181	172	189	184	190	191	195	198
Profit before tax	146	61	205	253	113	122	241	289	197	223	319	279	265	316	192	583	181	140	356	218	503	476	556	83	915	859	597	782	515	75	688	590	797	281	-88	442	409	529	163	-10	140	372
Tax	21	19	42	43	22	19	85	62	0	55	66	34	45	53	26	129	42	32	144	40	140	130	178	18	141	236	126	179	82	4	116	114	150	44	-82	33	96	91	-60	-3	40	75
Net profit	125	42	162	210	91	104	156	227	197	168	253	244	220	263	166	454	138	108	212	178	363	347	378	65	773	623	471	603	434	72	571	476	648	237	-6	409	313	439	223	-7	101	297
EPS ₹	7.44	2.52	9.65	12.49	5.40	6.16	9.27	13.50	11.68	9.98	14.99	14.48	13.02	15.53	9.80	26.82	8.17	6.37	12.49	10.47	21.38	20.41	—	3.82	45.47	36.63	27.71	35.42	25.45	4.20	33.54	27.92	37.96	13.89	-0.33	24.13	18.91	26.49	13.46	-0.44	6.07	17.90
Revenue YoY	—	—	—	—	10.5%	36.5%	15.8%	10.0%	19.8%	0.8%	2.4%	6.1%	15.2%	32.3%	14.9%	33.5%	27.0%	15.7%	32.8%	6.3%	28.0%	34.3%	32.1%	0.9%	28.4%	19.7%	10.7%	47.7%	-8.4%	-16.8%	2.8%	-6.1%	16.8%	12.9%	-12.3%	-15.2%	-9.3%	5.8%	0.1%	-2.4%	-14.2%	-1.8%
Profit YoY	—	—	—	—	-27.2%	145.1%	-3.8%	8.3%	116.5%	62.5%	62.1%	7.5%	11.7%	56.0%	-34.5%	85.7%	-37.1%	-58.9%	27.7%	-60.9%	162.1%	220.9%	78.5%	-63.5%	113.0%	79.8%	24.7%	829.3%	-43.9%	-88.5%	21.2%	-21.1%	49.3%	230.8%	-101.0%	-14.0%	-51.6%	85.3%	—	-101.8%	-67.8%	-32.3%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 32 periods

	DEC '18	MAR '19	JUN '19	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	14.1%	13.9%	15.3%	19.4%	12.0%	12.9%	12.3%	10.3%	13.9%	11.0%	9.8%	11.1%	11.0%	7.7%	11.9%	11.6%	11.6%	14.0%	14.9%	9.3%	9.3%	5.0%	4.9%	8.6%	13.2%	16.9%	16.9%	16.0%	15.5%	11.1%	8.5%	7.2%
ROCE	11.9%	13.7%	15.6%	16.7%	10.3%	11.1%	11.3%	11.8%	16.4%	14.4%	12.7%	14.5%	17.9%	13.8%	18.0%	19.5%	22.6%	25.0%	26.6%	25.6%	26.3%	24.6%	24.8%	21.2%	21.5%	21.0%	21.2%	19.3%	18.6%	13.0%	10.1%	8.9%
Net margin	11.8%	12.6%	13.8%	16.5%	9.9%	11.5%	10.6%	8.8%	11.6%	10.2%	8.9%	9.6%	9.3%	6.8%	10.5%	10.7%	10.1%	13.2%	13.3%	8.8%	8.7%	5.0%	4.8%	8.8%	13.0%	17.3%	16.9%	16.8%	16.1%	12.5%	9.7%	8.5%
EBITDA margin	19.3%	20.4%	20.1%	20.7%	13.7%	14.1%	15.7%	16.2%	20.1%	20.3%	17.8%	18.0%	20.9%	17.5%	18.2%	20.1%	21.9%	25.6%	28.4%	28.2%	28.0%	28.3%	27.6%	26.8%	26.6%	26.0%	25.4%	24.6%	23.3%	19.1%	15.5%	14.7%
Debt / equity	0.40	0.24	0.24	0.24	0.24	0.11	0.11	0.11	0.11	0.15	0.15	0.15	0.15	0.16	0.16	0.08	0.08	0.06	0.06	0.05	0.05	0.06	0.06	0.14	0.14	0.12	0.12	0.12	0.12	0.17	0.17	0.15
Interest coverage	25.53	26.78	27.45	26.85	17.98	19.61	21.36	23.61	31.61	30.23	27.69	32.40	38.66	32.22	36.17	36.91	36.55	43.10	45.07	45.86	47.92	43.00	38.24	31.81	27.26	28.08	26.12	24.41	22.53	15.39	10.67	8.82
Asset turnover	0.66	0.69	0.69	0.74	0.76	0.75	0.78	0.78	0.81	0.72	0.74	0.77	0.78	0.72	0.73	0.77	0.82	0.76	0.81	0.77	0.78	0.72	0.74	0.64	0.67	0.66	0.68	0.63	0.64	0.58	0.57	0.57

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	85	85	85	83	83	83	83	83	83	83	83	83	83	83	83	84	84	84
Other equity / reserves	7,780	9,768	12,484	12,179	12,489	13,941	15,516	17,558	19,129	20,692	23,203	25,413	28,171	30,666	33,466	35,930	37,808	38,724
Total equity	7,865	9,853	12,570	12,262	12,572	14,024	15,599	17,642	19,212	20,775	23,286	25,497	28,255	30,749	33,550	36,014	37,892	38,807
Borrowings	4,136	3,617	3,340	4,908	5,065	3,412	1,784	2,694	3,088	1,729	1,347	1,323	1,652	4,382	4,184	4,496	6,294	5,826
Current liabilities	5,790	6,821	6,347	8,420	6,894	5,897	7,214	8,104	9,766	7,987	8,572	8,406	9,588	12,921	13,034	15,104	16,747	15,430
Non-current liabilities	2,374	1,923	1,467	1,134	3,079	2,545	412	871	769	407	427	906	1,021	2,664	2,465	2,896	3,145	3,075
Total assets	16,030	18,598	20,384	21,816	22,544	22,466	23,225	26,617	29,747	29,169	32,285	34,809	38,864	46,728	49,427	54,373	58,123	57,631
Property, plant & equipment	3,750	4,184	4,613	5,028	4,973	4,913	4,778	4,732	4,887	5,167	5,654	5,850	6,249	6,726	7,298	9,119	10,078	10,269
Capital work-in-progress	639	529	663	610	768	472	436	954	1,280	1,161	975	1,151	1,351	1,852	2,399	1,997	1,460	1,207
Investments	1,067	2,248	131	160	—	2,334	2,402	1,874	2,184	1,990	4,986	4,457	4,930	3,663	4,051	4,701	5,285	4,502
Inventories	2,419	2,570	2,558	2,853	2,909	3,358	3,507	4,541	5,088	4,904	4,867	5,659	6,355	7,204	7,108	7,582	7,653	8,118
Receivables	3,325	4,101	4,125	3,820	4,070	3,998	5,202	4,976	6,682	7,699	7,248	6,972	8,030	8,440	9,042	9,775	10,123	10,140
Cash & equivalents	2,301	1,872	492	386	264	223	205	1,483	1,485	910	578	1,354	711	1,133	1,465	991	1,537	1,329

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 13 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	1,970	2,524	3,263	2,144	1,803	2,870	2,984	3,570	2,811	5,887	4,543	4,643	5,674
Cash from investing	-1,694	-2,265	-2,039	-1,840	-1,488	-773	-492	-2,266	-2,639	-4,137	-4,028	-5,102	-6,549
Cash from financing	-24	-433	-1,700	-369	-444	-2,133	-2,516	-30	-242	-2,686	-376	1,186	829
Capex	1,083	1,532	1,482	4,093	—	—	—	—	1,905	1,886	2,744	3,440	3,840
Free cash flow	887	992	1,781	-1,949	—	—	—	—	906	4,001	1,800	1,203	1,833
Dividends paid	298	359	411	339	399	400	392	415	415	498	665	666	666

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹10,269 cr18%

CWIP

₹1,207 cr2%

Investments

₹4,502 cr8%

Inventories

₹8,118 cr14%

Receivables

₹10,140 cr18%

Cash & equivalents

₹1,329 cr2%

Other assets

₹22,066 cr38%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+14.1%

6 months+5.0%

1 year+9.8%

3Y CAGR+8.7%

5Y CAGR+7.5%

10Y CAGR+8.3%

50-day avg₹1,224.27

200-day avg₹1,249.38

RSI (14)84

Long-term financials (FY12–FY12)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY12	₹9,814 Cr	₹1,804 Cr	₹1,301 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Dr. Reddy's Laboratories Ltd. with

Laurus Labs vs Dr. Reddy's Laboratories Apollo Hospitals Enterprise vs Dr. Reddy's Laboratories Zydus Lifesciences vs Dr. Reddy's Laboratories Dr. Reddy's Laboratories vs Cipla Dr. Reddy's Laboratories vs Mankind Pharma Dr. Reddy's Laboratories vs Aurobindo Pharma

FAQs

What is the share price of Dr. Reddy's Laboratories Ltd.?

Dr. Reddy's Laboratories Ltd. (DRREDDY) closed at ₹1,373.00 on NSE on 06 Nov 2026.

What is the market cap of Dr. Reddy's Laboratories Ltd.?

₹1,14,646 crore at the latest close.

What is the P/E ratio of Dr. Reddy's Laboratories Ltd.?

40.9, on trailing-twelve-month earnings from its filings.

How fast is Dr. Reddy's Laboratories Ltd. growing?

Dr. Reddy's Laboratories Ltd.: revenue has compounded at 11.0% a year over three years; net profit at -2.4% a year. Latest-quarter revenue is down 1.5% year on year, profit down 31.3%.

How profitable is Dr. Reddy's Laboratories Ltd.?

On a trailing-twelve-month basis return on equity is 7.2%, return on capital employed 8.9%, operating margin 14.7%, net margin 8.5%.

How much debt does Dr. Reddy's Laboratories Ltd. have?

Dr. Reddy's Laboratories Ltd. is lightly geared: debt to equity is 0.15 with borrowings of ₹5,826 cr against cash of ₹1,329 cr (balance sheet of 2026-09-30). Operating profit covers interest 8.8 times.

Financials parsed from Dr. Reddy's Laboratories Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.